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Influenza viruses have been known for more than 20 yr to incorporate anti- 
gens  derived  from  the  cells  in  which  they  are  grown  (1, 2).  Components 
resembling Forssman, blood group, and infectious mononucleosis antigens have 
been  described  (3, 4).  The  most  widely  studied  of  these  host  antigens  is 
a  sulfated mucopolysaccharide present in chick liver, bile, and allantoic cells 
that becomes intimately associated with influenza viruses growing in the chick 
allantoic cavity (5, 6). 
Some strains of influenza A virus, derived either from fowl plague (7) or from 
neurotropic variants of human influenza virus (8), can be grown in nonspecific 
mouse tumors where they exert an oncolytic effect. When the experiment is 
performed  in  mice  that  are  genetically  resistant  to  the  lethal  action  of 
the oncolytic virus, viral oncolysis is followed by the development of a  solid 
antitumor immunity mediated by ~G-immunoglobulins (9, 10). This in itself is 
not surprising, since nonspeciflc tumors represent allografts. More surprising, 
however, are the following observations: Whereas tumor cell homogenates pre- 
pared by mechanical disruption and lyophllization are not immunogenic, or at 
best  are  very weakly so,  similar homogenates prepared  from virus-infected 
tumors are highly immunogenic (10). 
In order to explain the enhancing role of the virus on the immunogenicity of 
the tumor, it was conjectured that weak antigens or haptens derived from the 
host tumor cell might become associated with or incorporated into the virus and 
thus  turn  into  potent  immunogens  (10,  11).  We  present  evidence  here 
that strongly suggests that this indeed is the case. 
Materials  and Methods 
Mice.--ICR/Vet  mice (random-bred) were obtained from the  Department of Animal 
Husbandry, Veterinary School, University of Zurich, Switzerland. A2G]Exm mice (hence- 
forth called A2G) were bred by brother-sister mating from nuclei of A2GICFW/Lae  supplied 
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by the Laboratory Animals Centre, Carshalton, Surrey, England. A2G mice are genetically 
resistant to influenza A viruses (12,  13).  Mice were 8-10 wk old at the beginning of experi- 
ments. Experimental groups were matched with respect to age and sex. 
Tumor.--The strain of Ehrlich ascites (EA)  tumor used in the present experiments has 
been described previously (11). The tumor was maintained in male A2G mice by weekly in- 
traperitoneal (i.p.)  injections of  106 washed tumor cells. Cells from the  125th to the 160th 
serial passage in A2G mice were used. Periodic checks on the minimum number of cells re- 
quired to induce fatal ascites in A2G mice of both sexes confirmed that the LDS0 was close to 
10 cells per mouse (11). Tumor challenge in the experiments to be described was always 1000 
washed EA cells administered i.p.  (100 LDSO). In each experiment, an additional untreated 
control group of four mice (not shown in the tables) received a challenge of 100 EA cells. All 
these mice died of tumor ascites. 
Viruses.--The  WSA strain of neurotropic, tumor-adapted influenza A  virus (8) used was 
the same as that used in previous experiments (9,  10,  11).  Virus stock was prepared from 
Ehrllch ascites tumor grown in ICR/Vet mice and infected on day 6 with 10' EID60 of WSA 
virus. After 48 hr, the oncolytic tumor was harvested, homogenized, and lyoph~l~7.ed in 0.2 
mi  amounts.  The  ampoules  were  sealed  under  vacuum  and  kept  at  --10°C. 
The TUR strain of fowl plague virus was A/Turkey/Engiand/63 obtained from Dr. H. G. 
Pereira, World Influenza Centre, Mill Hill, London. This virus was adapted to growth in EA 
cells by serial passages.  From the fourth passage, it produced changes in EA tumor indis- 
tinguishable from those induced by WSA.  Stock tumor-grown TUR was prepared from the 
10th serial passage of TUR in EA tumor cells grown in ICR/Vet mice in the same manner as 
that described for WSA. 
The Lee strain of influenza B virus was an old laboratory strain. Stock capillary tubes con- 
tainlng infected allantoic fluid were kept over dry ice. 
Egg-Grou~ Virus.-- 
WSA : A lyophilized ampoule of stock WSA was diluted 10  -6 and inoculated allantoically 
into 10 day old embryonated eggs.  The virus was harvested after 2 days incubation at 35°C. 
Capillary tubes were prepared from one infected fluid and stored over dry ice. Capillaries 
from this stock were then used to inoculate batches of l0 day old eggs at a  dilution of 10  -4. 
These eggs were incubated for 3 days at 35°C. The allantoic fluids were harvested, pooled, 
and subjected to two cycles of differential centrifugation in the cold,  each consisting of a 
low speed run at 1000 g for 10 rain and a  high speed run at  105,000  g for 30 rain. The final 
sediment was resuspended in about one twentieth of the original volume and subjected to a 
third low speed centrifugation. The final suspension was adjusted to a  hemagglutinin (HA) 
titer of 1:1600. 
TUR: The preparation of egg-grown TUR virus was similar to that described for WSA, 
with the following exceptions: The inoculum consisted of infected allantoic fluid from an 
early egg passage of TUR virus which had never been passed in ascites tumor or in mice; eggs 
were incubated for 48 hr only. The final suspension was adjusted to a  HA titer of 1:1600. 
Lee: The preparation of  egg-grown Lee  virus was  similar to  that described  for  WSA, 
except for the inoculum which consisted of Lee aUantoic virus stock. The final suspension was 
adjusted to an HA titer of  1:3200. 
Antisera.--Rabbit  antisera to egg-grown WSA and TUR  viruses were prepared  by one 
intramuscular injection of egg-grown virus emulsified in Freund's complete adjuvant (Difco 
Laboratories, Inc., Detroit, Mich.), followed 21 days later by one intravenous injection of egg- 
grown virus. Sera were collected 10 days after the intravenous injection, and inactivated at 
56°C for 30 rain before use.  Hemagglutination-inhibition (HAI)  titers of the two  sera most 
extensively used in the present experiments are shown on Table V. 
Anti-WSA gamma globulin was prepared from 20 ml of rabbit anti-WSA serum by pre- 
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column equilibrated with 0.0175 •  sodium phosphate buffer pH  6.3  (14). At 2 mg/ml this 
preparation had an HAI titer of 1:1600 against WSA and showed a single sedimentation peak 
with an s20.w value of 6.5 in the analytical ultracentrifuge. 
HA  Titratio~ and HAI  Tests.  u  HA titrations were done in Perspex hemagglutination 
trays with 0.5% washed fowl erythrocytes. Sedimentation patterns were read when the nega- 
tive control cups had formed compact buttons. HA titers indicate highest virus dilution giving 
partial or complete agglutination. HAI titrations were performed by mixing serial serum dilu- 
tions with four agglutinating doses of virus. After 30 rain at room temperature, fowl red cells 
were added. The patterns were read as above. HAI titers indicate highest serum dilution at 
which partial or complete inhibition of agglutination occurred. 
Preparation of Viral Oncolysal~.--Adult ICR mice of either sex were inoculated i.p. with 
106 washed EA cells. After the tumor had grown for 7 to 8 days, 105 EIDs0 of WSA- or TUR- 
lyophilized stock virus were inoculated into the ascites. Within 48 to 72 hr oncolysls occurred, 
as evidenced by a  striking reduction of abdominal tension and ruffling of hair (9). Animals 
showing definite tumor collapse were sacrificed, their peritoneal cavities were opened, and 
the solidified tumor masses were removed aseptically with forceps. This pooled material was 
stored at  --20°C.  To prepare homogenates, the material was thawed, homogenized with a 
Sorvall omnimixer, frozen and thawed again, and centrifuged in the cold at  5000 g for 30 
rain. The supernatant was distributed in ampoules and lyophillzed. The ampoules were sealed 
under vacuum and stored at  --10°C.  WSA oncolysates, when reconstituted with distilled 
water, had HA titers of 1:32 to 1:320 and egg infectivity titers of 108 to 109 EIDs0 per mil- 
liliter. TUR oncolysates had HA titers of 1:800 to 1:1600 and egg infectivity titers of 108 to 
109 EIDs0 per milliliter. 
Egg Inf~ti~y T/trations.--Infectivity for eggs was determined by allantoic inoculation 
of 10 day old eggs as described previously (12). Eggs inoculated with WSA virus were opened 
after 3 days and their allantoic fluids were tested for HA. Eggs inoculated with TUR were 
observed for 3 days and the deaths were recorded. Titers are expressed as 50% egg-infecting 
doses (EID~0)  per milliliter. 
Absorpgon of WSA On~olysate with Fowl Erythrocytes and Elution with Receptor-Destroying 
Enzyme.--The following procedures refer to the experiment presented in Table IIL 2 mi of 
packed, washed, fowl erythrocytes were added to 100 ml of WSA oncolysate (HA titer 1:32). 
The mixture was gently agitated every 10 min for 1 hr at +4°C. After centrifugation for 10 
rain at 300 g, the supematant (which l~ad no measurable HA activity) was set apart. The sedi- 
mented erythrocytes were washed four times with saline and once with calcium saline (saline 
with 0.1% CaCI2 added). A portion of these cells was set apart for testing of immunogenicity. 
The remaining erythrocytes were resnspended in 5 ml oI calcium saline containing 1000 #g 
units of purified neuraminidase (General Biochemicals, Chagrin Falls, Ohio) and incubated at 
37°C for 30 min in a roller drum. The neuraminidase-erythrocyte mixture was then centrifuged 
at 300 g for 10 rain. The sedimented erythrocytes were washed once with saline and the wash 
supernatant added to the first supernatant containing most of the virus. These combined 
supematants were centrifuged at 105,000  g for 30 min to sediment the virus. The pellet was 
resuspended in 3 ml of saline (HA titer 1:320). Recovery of the virus in terms of hemagglutinin 
was about 30%. Erythrocytes were tested for their immunogenic properties at a concentration 
of 2.5% (v/v). 
Parallel absorption-elution procedures were carded out on a batch of allantoic fluid infected 
with WSA and adjusted to the same HA titer. Recovery of egg-grown virus was close to 50%. 
Aliquots of the material obtained at various stages of absorption and elution of egg-grown 
virus were tested in parallel with the corresponding materials from tumor-grown virus. None 
of the egg-derived samples showed any immunizing activity against EA tumor. For the sake 
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Saline.--Saline  refers to a solution containing 8.0 g NaCI, 2.7 g Na2HPO4.TH~O and 0.4 
g KH2PO4 per liter, pH 7.2. 
RESULTS 
1.  Immunizing  Power  of  Viral  Oncolysates.--When  0.02--0.5  ml  of  re- 
constituted  lyophllized  viral  oncolysates  (see  Materials  and  Methods)  were 
inoculated once intraperitoneally into A2G mice, significant protection against 
challenge with 1000 to 100,000  EA cells (100 to 10,000  LDs0) could be observed. 
The challenge was given 11 days after the immunizing injection, but no study 
was made of the optimal time interval for challenge. WSA oncolysates and TUR 
oncolysates behaved similarly. Table I  shows a representative experiment with 
a  WSA  oncolysate.  The  oncolysates induced  a  serologic antitumor  response, 
detectable on the 9th day, in vitro by tumor cell agglutination and in vivo by 
TABLE  I 
Induction of Immunity to Ehrlich Ascites Tumor in A2G Mice by WSA Oncolysate 
Treatment* 
Saline 
WSA oncolysate 1: 5:~ 
WSA oncolysate 1:15 
WSA oncolysate 1  :  45 
Result of challenge* 
0/8 
8/8 
8/8 
2/8 
* 0.5 ml i.p. on day 0. Challenge, 1000 EA cells. 0.5 ml i.p. on day 11. Final reading on 
day 39. Number of survivors per total number of mice in group. 
For preparation of oncolysates as mentioned in this and the next tables, see Materials 
and Methods. 
passive  protection  of  syngeneic  mice  against  EA  cells  (10,  11).  Mice  also 
responded to the virus contained in the oncolysate with a specific antiviral anti- 
body response. HAI titers against the homologous virus ranged from 1:160 to 
1:1240,  10-20 days after the injection  of WSA oncolysate, and  from 1:40  to 
1 : 160 after TUR oncolysate. 
To assess the possibility that a continuing viral infection was a cause of resist- 
ance to reimplantation of tumor cells,  the following data were obtained: 
(a)  The peritoneal cavities of six mice were rinsed with saline at the time of 
cbailenge,  and of six other mice 2 days after challenge when virus capable of 
multiplying in  the newly introduced  tumor cells should have been at a  peak. 
Each peritoneal washing was inoculated undiluted  and diluted  10  -1  ,  10  -2  , and 
10-  8  into  12  ten  day  old  eggs.  No  virus  could  be  recovered  from  any 
of the washings. 
(b)  Antiviral antibody was determined at the time of challenge in the sera of 
10 mice immunized with WSA oncolysate. The average HAI titer against WSA 
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(c)  A WSA oncolysate with an HA titer of 1:64 and an egg infectivity titer 
of los EID~o/m] was treated with 0.08 %  (v/v) of formaldehyde overnight at 
37°C. No residual infectivity could be detected in this material when dilutions 
los through 10  -2 were inoculated into eggs. Each of eight A2G mice received 0.5 
ml of the inactivated oncolysate intraperitoneally. All these mice survived chal- 
lenge with 1000 EA cells 11 days later. Their average HAI titer against WSA 
was 1:160. 
TABLE  II 
Failure o/Meckanical Lysates of Tumor Cells to Immunize A2G Mice Against 
Ekrlick Ascites Tumor 
Result of  Group  Treatment*  challenge* 
Saline 
WSA oncolysate 1: 5 
Mechanical lysate of Ehrlich ascites tumor ceils~ 
Egg-grown WSA virus§ 
Mechanical lysate of Ehrlich ascites tumor cells mixed with 
egg-grown WSA virusII 
O/8 
8/8 
0/8 
0/8 
0/8 
* 0.5 ml i.p. on day 0. Challenge, I000 EA cells. 0.5 ml i.p. on day 11. Final reading on 
day 39. Number of survivors per total number of mice in group. 
:~ l0  s EA cell equivalents per milliliter obtained by freezing-thawing and  homogeniza- 
tion in a Sorvall omnimixer. 
§ Influenza A virus, strain  WSA, concentrated and partially  purified from infected al- 
lantoic fluid by differential centrifugation (see Materials and Methods). HA titer 1:1600. 
I] Ultracentrifugal pellet of virus prepared as above  (group 4)  resuspended in EA ceil 
lysate  (as used in group 3). 
(d)  Finally, as shown below (section 4), mice actively immunized against the 
oncolytic virus could be protected by oncolysate and  even by oncolysate to 
which anfiviral antiserum had been added. It had previously been shown that 
active antiviral immunization of mice prevented oncolysis by WSA  virus  (9). 
In contrast to the ability of lysates from virus-infected tumor cells to induce 
antitumor immunity, both lysates from noninfected tumor cells and egg-grown 
virus  were  inactive.  Thus  a  mechanical  lysate  of  noninfected  tumor  cells 
prepared in their own ascitic fluid and containing an equivalent of l0  s EA cells 
per milliliter was not immunogevic. Egg-grown WSA virus, either as crude in- 
fected  allantoic  fluid  (HA  titer  1:160)  or  concentrated  by  differential 
centrifugation  (HA  titer  1:1600,  see  Materials  and  Methods)  induced 
high levels of HA1 antibodies but failed to immunize against the tumor, even 98  IMMUNOGENICITY  OF  VIRAL  ONCOLYSATES 
after repeated  injections.  Mechanically lysed noninfected  tumor  cells mixed 
with egg-grown WSA virus also failed to immunize against the tumor. A typical 
experiment is presented in Table II. 
2.  Attempts  at Separating the Immunogen from  the  Virus Particles in  Viral 
Oncolysates.--Since lysates from virus-infected tumor cells were immunogenic 
but lysates from noninfected tumor cells were not, we tried to separate the virus 
from  the  bulk  of  the  oncolysate.  The  immunogenic  activity  could  not 
TABLE III 
Absorption and Elution of Immunizing Principle  from Viral Oncolysate 
Result of  Group  Treatment*  challenge* 
Saline 
Chick red blood cells$ 
Egg-grown WSA virus adsorbed onto chick red blood cells 
WSA oncolysate 
WSA oncolysate after absorption with chick red blood cells 
Washed chick red blood cells used to absorb WSA oncolysate 
Same as above, but after RDE treatment 
RDE eluate from above, concentrated by ultracentrifugation 
Same as above diluted 1:10 
0/6 
0/6 
0/6 
11/12 
1/6 
10/12 
1/6 
6/6 
3/6 
* 0.5 ml i.p. on day 0. Challenge, 1000 EA cells. 0.5 ml i.p. on day 11. Final reading on 
day 39. Number of survivors per total number of mice in group. 
2.5% suspension in saline. For  details on the  other preparations,  see Materials  and 
Methods and text. 
be separated from the virus particles by differential centrifugation. An experi- 
ment on absorption and elution is shown in Table III. 
Absorption  of  viral  oncolysate  with  chick  red  cells  diminished  its 
immunogenicity  (group 5).  The chick red  ceils  that  had  absorbed the  virus 
proved immunogenic  (group 6).  The  immunogen could  be eluted  from such 
ceils  with  neuraminidase,  leaving  inactive  red  cells  behind  (groups  7, 8, 9). 
Parallel tests on virus grown in eggs showed lack of immunogenicity (group 3, 
and Materials and Methods). 
More  refined  attempts  at  purifying  the  virus  also  failed  to  separate 
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capacity  to  immunize  against  the  tumor.  Among  the  methods  used  were 
fractionation  on  DEAE  cellulose  (10)  and  sedimentation  in  sucrose  and 
potassium tartrate gradients. We shall not insist on details of these experiments 
here since they are open to the criticism that perfect purity of a virus suspen- 
sion is difficult to prove. 
3.  Inhibition  of  Immunogenic  Acti~i2y  of  Viral  Oncolysa2es  by  Rabbit 
Antiserum  to  Egg-Grovm  Virus.--When  viral  oncolysates  were  mixed  with 
potent rabbit antiserum prepared against egg-grown WSA virus and then in- 
TABLE IV 
Inhibition of Immunizing Activity of Viral Oncolysate by Rabbit Antibody to 
Egg-Grown Virus 
Antiviral  Result of  Group  Treatment*  responseS;  challenge~ 
Saline 
WSA oncolysate diluted 1:5 in saline 
WSA  oncolysate diluted  1:5  in  normal rabbit 
serum 
WSA oncolysate diluted 1:5 in rabbit anti-WSA 
WSA oncolysate diluted 1:5 in rabbit anti-WSA 
"},-globulin (2 mg/ml) 
<10 
640 
640 
<10 
<10 
0/6 
6/6 
6/6 
0/6 
3/12 
* 0.5 ml i.p.  on day 0.  For details of the various preparations used,  see Materials and 
Methods. 
~: As measured by hemagglutination-inhibition against four agglutinating doses of  egg- 
grown WSA. Figures show reciprocal of HA1 titer of pooled orbital bleedings on day 14. 
§ Challenge, 1000 EA ceils. 0.5 ml i.p. on day 11. Final reading on day 39. Number of sur- 
vivors per total number of mice in group. 
jected  into  A2G  mice,  both  the  antiviral  and  antitumor  responses  were 
suppressed.  The amount  of antibody added  was  sufficient to  neutralize the 
infectivity of the oncolysate for eggs. The same effects could also be produced 
with the gamma globulin fraction of the antiserum. Normal rabbit serum, includ- 
ing the preimmunization serum of the rabbit  from which  the  anti-WSA  had 
been obtained, was without effect. Table IV shows a representative experiment. 
Similar inhibition of immunogerdcity was observed when the rabbit antiserum 
was first injected intravenously 5 hr before intraperitoneal injection of viral 
oncolysate. 
Rabbit  antisera prepared against  egg-grown influenza B  virus,  strain Lee, 
did not inhibit the immunogenicity of WSA oncolysates when used at the same 
HAI concentrations as anti-WSA in experiments of the type shown in Table IV. I00  IM.M-UNOGENICITY OF VIRAL ONCOLYSATES 
However,  when  larger  amounts  of  anti-Lee  were  used,  a  slight  degree  of 
inhibition became apparent.  Since adjustment of antiserum concentration by 
HAI titer seemed an arbitrary procedure, it was felt that a satisfactory demon- 
stration of serologic  specificity required a different approach. 
Experiments  of  the  following  type  were  therefore  contemplated:  Two 
oncolytic viruses, X  and Y, were to provide oncolysates OX and OY, and the 
same viruses grown in eggs would be used to prepare rabbit antisera anti-EX 
and  anti-EY.  Proof  of  serologic  specificity  would  be  obtained  if  it  could 
be shown that anti-EX inhibited the immunogenicity of OX more than that 
of OY, while at the same time anti-EY inhibited OY more than OX. 
We  chose  the  WSA  virus  strain  for  X  and  the  TUR  virus  strain  for 
Y. Adaptation of the TUR strain to Ehrlich ascites tumor was easily achieved. 
A rabbit antiserum was prepared from the unadapted strain passed exclusively 
TABLE V 
Hemagglutination-Inhibition Studies with Rabbit Antieera to the WSA and TUR 
Strains of Influenza A  Virus 
Test virus*  Anti-WSA*  Anti-TUR§ 
WSA  2560  < 10 
TUR  < 10  5120 
* Four agglutinating doses of tumor-grown virus. Figures show reciprocal of HAI titer. 
Serum of a  rabbit immunized with egg-grown WSA (see Materials and Methods). 
§ Serum of a rabbit immunized with egg-grown TUR (see Materials and Methods). 
in eggs. Thus the virus used for immunizing the rabbit had never eDcountered 
tumor cell  antigens. TUR behaved very similarly to WSA during oncolysis. 
Both strains were influenza A viruses and hence shared the complement-fixing 
nucleoprotein antigen. Their surface antigens showed little cross-reactivity as 
judged from HAI tests (Table V). 
TUR oncolysates had essentially the  same characteristics as have already 
been  described  for  WSA  oncolysates.  The  results  of  a  cross-inhibition 
experiment with rabbit antisera are shown in Table VI. All control mice died 
(group  1),  as did mice pretreated with rabbit antiviral antiserum alone (not 
shown). Oncolysates mixed with homologous antiserum (WSA oncolysate + 
anti-WSA serum or TUR oncolysate +  anti-TUR serum)  had lost their im- 
mlmizing power (groups 3 and 6). However, the same concentration of antisera 
either did not inhibit the immunogenicity of heterologous oncolysates (group 7) 
or inhibited it very weakly (group 4). The antiviral response (not shown) fol- 
lowed the same pattern. 
4.  Enhancement of Imraunogenic Activity of Viral Oncolysates by Prior Active 
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immunized against the virus by intraperitoneal injections of egg-grown WSA 
and  then immunized with WSA oncolysate, the dose of oncolysate needed to 
achieve a  given level of immunity against the tumor was reduced. Table VII 
shows  a  typical  experiment.  High  levels of HAI antibodies  (titers  1:640  to 
1:12,560)  were induced by this preimmunization schedule.  In several experi- 
ments, primed mice required 4-16  times less oncolysate as unprimed mice to 
attain comparable levels of antitumor immunity. The relatively large numbers 
TABLE  VI 
Specificity of Inhibition  of Immunizing Adivily of Viral Oncolysales by 
Antidral Antiserum 
Group  Treatment* 
Saline 
WSA oncolysate diluted 1:5 in saline 
WSA oncolysate diluted 1:5 in rabbit anti-WSA:~ 
WSA oncolysate diluted 1:5 in rabbit anti-TUR§ 
TUR oncolysate diluted 1:5 in saline 
TUR oncolysate diluted 1:5 in rabbit anti-TUR§ 
TUR oncolysate diluted 1:5 in rabbit anti-WSA$ 
Result of 
challenge* 
0/6 
6/6 
0/6 
5/6 
6/6 
0/6 
6/6 
* 0.5 ml i.p. on day 0. Challenge, 1000 EA cells. 0.5 ml i.p. on day 11. Final reading on 
day 39. Number of survivors per total number of mice in group. 
~: Serum of a  rabbit immunized with  egg-grown WSA  (see Materials  and  Methods). 
HAI titer 1: 2560. 
§ Serum of a rabbit immunized with egg-grown  TUR (see Materials and Methods). HAI 
titer 1:5120. 
d  a nlraals  required  was  a  drawback  of these  experiments.  Thus  one  would 
hesitate to conclude from Table VII that priming with influenza B virus (group 
9) was without effect. A useful amplification of the difference between primed 
and unprimed mice was obtained in the following experiment. 
Mice were either primed by an injection of egg-grown WSA, by an injection 
of  egg-grown B/Lee,  or an  injection  of saline.  2  wk later,  one-third  of each 
group  received  injections  of  WSA  oncolysate,  one-third  injections  of  WSA 
oncolysate  mixed  with  rabbit  anti-WSA,  and  one-thlrd  injections  of  saline. 
II  days later,  all mice were  challenged  with  I000 EA  cells.  The results  are 
shown in Table VIII. 
All control mice died  (groups I, 4  and 7). All mice which had received on- 102  IMAfD-NOGENICITY OF  VIRAL  ONCOLYSATES 
colysate alone  survived (groups 2, 5 and 8). The unprimed mice that had re- 
ceived the mixture of oncolysate and antiserum died (group 3) as did the mice 
primed with heterologous virus (group 6). In mice primed with WSA, however, 
immunogenicity of the oncolysate was not abolished by antiserum (group 9). 
The results of these experiments are in line with the observation that a primary 
TABLE VII 
Effect of Priming with Egg-Grown WSA on Immunogenicity  of WSA O~ol 'sate 
Result of  Group  First treatment*  Second treatment*  challenge* 
Sa~ine 
Saline 
Saline 
Saline 
Egg-grown WSA~ 
Egg-grown WSA 
Egg-grown WSA 
Egg-grown WSA 
Egg-grown B/Lee§ 
Saline 
WSA oncolysate diluted i: 20 
WSA oncolysate diluted 1:40 
WSA oncolysate diluted I: 80 
Saline 
WSA oncolysate diluted I: 40 
WSA oncolysate diluted i: 80 
WSA oncolysate diluted 1:160 
WSA oncolysate diluted 1:40 
o/6 
6/6 
3/6 
o/6 
0/6 
6/6 
6/6 
5/6 
4/6 
* First treatment, 0.1  ml i.p. on day 0.  Second treatment,  0.5 ml i.p. on day 14. Chal- 
lenge, 1000 EA cells.  0.5 ml i.p. on day 25.  Final reading on day 53. Number of survivors 
per total number of mice in group. 
~t Influenza A  virus, strain  WSA, concentrated  and  partially purified from infected al- 
lantoic fluid (see Materials and Methods). HA titer 1:1600. 
§ Influenza  B  virus,  strain  Lee,  concentrated  and  partially purified  from  infected  al- 
lantoic fluid (see Materials and Methods). HA titer 1:3200. 
antigenic  stimulus  can  easily  be  inhibited  by  antibody  excess,  whereas  a 
secondary stimulus cannot (15, 16, 17). 
DISCUSSION 
A single intraperitoneal  injection of a viral oncolysate induced a significant 
level of resistance to challenge  with tumor cells. This resistance could not be 
attributed to a recapitulation of oncolysis for the following reasons: No virus 
could be recovered at the time of challenge;  high levels of antiviral antibodies 
were present; inactivation  of the virus by formalin did not abolish immuno- 
genicity; mice actively preimmunized against the virus could be protected by JEAN  LINDEI~NN  AND  PAUL A. KLEIN  103 
viral  oncolysate  and by viral  oncolysate  to  which  neutralizing  amounts of 
antiviral  antibody had  been  added. 
When we first observed  antitumor immunity following viral oncolysis, we 
considered the possibility that the immunogenicity d  certain structures of the 
TABLE VIII 
Effect of Priming with Egg-Grown WSA  on Immunogenlcity  of WSA Oncolysate Mixed with 
Rabbit Anti-WSA 
Result of  Group  First treatment*  Second treatment*  challenge* 
SaUne 
Saline 
Saline 
Egg-grown B/Lee§ 
Egg-grown B/Lee 
Egg-grown B/Lee 
Egg-grown WSA [[ 
Egg-grown WSA 
Egg-grown WSA 
Saline 
WSA oncolysate diluted 1:5 in saline 
WSA oncolysate diluted 1 : 5 in rabbit anti- 
WSM: 
Saline 
WSA oncolysate diluted 1:5 in saline 
WSA oncolysate diluted 1:5 in rabbit anti- 
WSA~ 
Saline 
WSA oneolysate diluted 1:5 in saline 
WSA oncolysate diluted 1:5 in rabbit anti- 
WSA~ 
0/4 
4/4 
O/4 
o/4 
4/4 
o/4 
o/4 
4/4 
4/4 
* First treatment, 0.1 ml i.p. on day 0. Second treatment, 0.5 ml i.p. on day 14. Chal- 
lenge, 1000 EA ceils. 0.5 ml i.p. on day 25. Final reading on day 53. Number of survivors 
per total number of mice in group. 
Serum  of  a  rabbit immunized with  egg-grown WSA  (see Materials  and Methods). 
HAI titer 1: 2560. 
§ Influenza B  virus,  strain Lee,  concentrated  and partially purified from infected  al- 
lantoic fluid (see Materials and Methods). HA titer 1:3200. 
]] Influenza A virus,  strain WSA, concentrated  and partially purified from infected al- 
lantoic fluid (see Materials and Methods). HA titer 1:1600. 
tumor cell might be increased when they became  associated  with or incorpo- 
rated into the virion (11). We can now offer some evidence in favor of this 
view. 
(a)  Egg-grown  WSA virus alone or mixed with mechanically lysed,  unin- 
fected tumor cells was incapable  of inducing antitumor immtmity. 
(b)  When the virions were isolated from the bulk of the viral oncolysate by 
differential  centrifugation, adsorption to and elution from red cells, and other 104  /MMITNOGENICITY  01  ~ VIRAL  ONCOLYSATES 
procedures, the capacity to induce antitumor immunity could not be separated 
from the virus.  This is a comparatively weak argument at the present stage of 
our attempts to purify the virus. 
(c)  The  immunizing  activities  of  viral  oncolysates  both  with  respect  to 
antiviral  (HA1)  antibody  and  antitumor  immunity,  could  be  abolished  by 
rabbit antibody to egg-grown  virus. This effect was mediated by the gamma 
globulin fraction of the rabbit antiserum and showed serologic specificity. 
(d)  The immunizing  activities of viral oncolysates were enhanced by prior 
vaccination of mice with homologous egg-grown virus. This effect again showed 
serologic specificity. 
Since  the  rabbit  antisera  were  prepared  against  egg-grown  virus,  they 
should  have  recognized  virus-specific  and  chick-specific  antigens  only.  The 
host component of tumor-grown virus may have cross-reacted with antibody 
to the chick-specific component of egg-grown virus. If this were so, one would 
have expected that mice could be immunized against the tumor with egg-grown 
virus. Several attempts to demonstrate this have failed.  Also, antisera induced 
by different strains of egg-grown influenza  virus should have shown extensive 
cross-inhibition  of  immunogenicity.  But  the  serologic  specificity  observed 
points instead  to  the  virus-specific  component  of tumor-grown  virus  as  the 
target of the rabbit antibody. 
One difficulty in this concept is that antibody directed against only part of the 
antigenic determinants of a complex antigen seems to inhibit the immunogenic- 
ity of the whole antigen.  This probably means that the host antigen is an inte- 
gral  part  of the virus and  not merely an  adventitious contaminant.  Similar 
intimate integration of host antigen has indeed been shown to occur in influ- 
enza virus: Antibody directed against one particular host component inhibits 
hemagglutination  by the virus (5, 6).  A possible analogy is presented by the 
decreased risk of Rh sensitization  of mothers who are incompatible with their 
foetus with respect to the ABO group (18). Whatever explanation is contem- 
plated, it is difficult  to escape the conclusion  that the immunogenicity of viral 
oncolysates must be in some way associated with the virus,  since  it  was  the 
virus which provided the only link between oncolysate and rabbit antibody in 
our experiments. 
The  same  conclusions  follow  experiments on mice primed  with  egg-grown 
virus. Here again  it could be argued that the chick-specific component of egg- 
grown virus, although by itself unable to induce antitumor immunity, primed 
the  mice  with  respect  to  cellular  antigens  in  viral  oncolysates.  Additional 
assumptions  are  necessary to  account  for  the  serologic  specificity  observed. 
We prefer the alternative explanation that the mice were primed by the virus- 
specific antigens.  It may seem difficult at first to understand why priming with 
one antigen should be followed by an anamnestic response  to a novel antigen. 
This, however, is a well-recognlzed phenomenon and represents the less obvious 
facet of so-called "original  antigenic  sin" (19). In the words of Fazekas de St. JEAN  LINDENMANN  AND  PAUL  A. KLEIN  105 
Groth and Webster, "the Original  Antigenic Sin is manifested by a secondary 
response to a foreign substance the organism is experiencing for the first time" 
(20).  Another useful analogy is provided by examples of enhanced  antibody 
response  to  a  hapten-carrier  complex  after priming  with  carrier  alone  (21). 
This is said to occur only when the priming  injection elicits  delayed hyper- 
sensitivity (22). We have not studied this aspect in our mice, but it is known 
that influenza viruses induce a state of delayed allergy in man (23). 
All mice passively immunized with rabbit antiviral antiserum and mice ac- 
tively immunized with egg-grown  virus had high  titers of HAI antibody di- 
rected against  the oncolytic virus.  Whereas  the first procedure  (passive im- 
munization)  abolished immunogenicity, the second procedure (active immuni- 
zation) enhanced the immunogenicity of the viral oncolysate. This paradox is 
easily resolved. Primary immunization  can be inhibited by antibody excess; a 
secondary response,  however, is little affected by either actively acquired or 
passively administered antibody (15, 16, 17). This was strikingly demonstrated 
in  experiments in which  the  same oncolysate-antibody mixture  was not im- 
munogenlc in unprimed mice or in mice primed with heterologous virus,  but 
was immunogenic  in  mice primed  with  homologous egg-grown  virus  (Table 
VIII). 
Quantitation in our experiments was relatively  crude, and we cannot state 
the precise  degree of serologic  specificity  involved.  No exact parallelism  need 
be expected with any of the serologic  groupings currently recognized among 
influenza  viruses,  particularly  if delayed hypersensitivity  should prove essen- 
tial  for priming. A  number of experiments suggest themselves. For instance, 
rabbit antisera  to a whole spectrum of influenza  viruses  could be used to pin- 
point the antigenic structure most closely  associated  with the immunogen. 
Another approach to the same problem would be the preparation of highly 
purified  virus  from virus-infected  tumor and its fractionation  into subunits. 
Also, the time at which tumor homogenates first  become immunogenic after 
viral infection  might give  important clues. 
Several reports  indicate  that viral  oncolysis  leads  to tumor immunity. Thus, 
oncolysis by arboviruses was followed by solid  immunity  to several trans- 
plantable tumors (24,  25).  The same was true  of onco]ysis  by tumor-adapted 
influenza  virus (9,  I0, II, 26).  Tumor cells  infected  in  vitro  with influenza  virus 
induced immunity to the tumor (27).  A  tumor-adapted strain  of Newcastle 
disease  virus  led to oncolysis  and postoncolytic  tumor immunity (28),  as did a 
strain of reovirus type 3 (29). 
The question arises  whether incorporation  of host materials into the virus 
is a common feature of all of these experiments.  Influenza and Newcastle dis- 
ease viruses are known to incorporate host materials into their envelopes (1, 2, 
3, 4, 5, 6, 30, 31, 32). Sindbis,  an arbovirus, contains host-derived antigens (4). 
The situation is less clear with reovirus, possibly because of lack of work on 
this aspect. Besides incorporation of host antigens into virions,  other means of 106  IMMUNOGENICITY  OF  VIRAL  ONCOLYSATES 
enhancing immunogenicity  by viral infection are conceivable (33). The increase 
of cellular immunogenicity just described might be related to some forms of 
induction of "neoantigens" by oncogenic viruses.  Although it is usually as- 
sumed that these antigens are coded for in the genome of the virus, alternative 
explanations  may exist. For instance,  it has been suggested that the common 
complement-fixing  antigen of the avian leucosis group  of viruses  could be  a 
normal chick component (34). 
The possibility of vaccinating animals with the viral agent prior to injecting 
them with virus-infected  cells opens new perspectives  for the study of virus- 
enhanced immunogenicity of tumors and other tissues. It would no longer be 
necessary to use mice genetically resistant to certain oncolytic viruses, such as 
PRI (25) or A2G (9), or to use viruses of intrinsically low virulence,  such as 
NDV (28) or reo 3 (29). Neither would the choice of viruses have to be limited 
to those  having dramatic oncolytic  effects. Infection of the cells could  take 
place either in vivo, as in the experiments presented  above, or in vitro, as per- 
formed by others (27). In vivo infection would offer the advantage of much 
higher cell density. 
There is no evidence  that tumor-specific  target antigens rather than allo- 
antigens are  involved  in  the system we have studied.  It remains  for future 
experiments  to elucidate  the behavior  of tumor-specific antigens during viral 
infections. 
Much speculation but relatively few facts support the idea that viruses play 
an important role in initiating autoimmune disorders (33). It has recently been 
possible to induce  an autoantibody to an antigen present in chicken  bile by 
immunization of chickens  with  egg-grown influenza  virus  (35). Our  experi- 
ments demonstrate that,  in  the mouse,  cellular  structures  of low  immuno- 
genicity, perhaps haptens, become potent immunogens  when  integrated into 
the  makeup of viral  particles.  Similar  phenomena may be  involved  in  the 
immunopathology of certain diseases. Experiments modeled on the oncolytic 
system outlined above might shed some fight on this area. 
SUMMARY 
A2G mice could be solidly immunized against the Ehrlich ascites  tumor by 
single intraperitoneal injections  of homogenized  and lyophilized  tumor cells 
which had been  infected with oncolytic  strains of influenza A virus.  Similar 
homogenates  from  noninfected  tumor  cells were  not  immunogenic,  even 
when mixed with egg-grown virus. 
The immunizing principle in viral oncolysates  could not be separated from 
the oncolytic virus by differential  centrifugation or adsorption to and elution 
from red cells. It could be inhibited by antibody raised in rabbits against the 
egg-grown oncolytic virus. This reaction showed serologic specificity. Thus, the 
immunogenicity  of an oncolysate produced with the WSA strain of neurotropic 
influenza virus could be inhibited by rabbit anti-WSA, but not by rabbit anti- JEAN LINDENMANN  AND PAUL A. KLEIN  107 
body to the TUR strain of fowl plague virus. Conversely, the immunogenicity 
of an oncolysate prepared with the TUR strain could be inhibited by rabbit 
anti-TUR, but not by anti-WSA. 
When mice were preimmunized (primed) with egg-grown WSA virus,  their 
antitumor response to a  later injection of WSA oncolysate was of the anam- 
nestic type. Priming with egg-grown influenza B virus had no such effect. 
It was concluded  that the immunogenicity of certain host cell components 
was greatly increased by incorporation into the makeup of the oncolytic virus. 
We thank Dr. P. A. Miescher for helpful criticism and Mrs. M. Acklin and Miss A. Brunet 
for able technical assistance. 
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